Setidegrasib

Setidegrasib is an investigational new drug that is being evaluated by Astellas Pharma for the treatment of solid tumors. It is an PROTACs degrader of the KRAS protein harboring a G12D mutation.
Wikipedia contributors, "Setidegrasib", Wikipedia, revision 1377082559, retrieved 20 November 2026, source, CC BY-SA 4.0.